SAN DIEGO, Jan. 9 /PRNewswire/ -- Cardium Therapeutics, Inc. and its parent Aries Ventures Inc. announced that a Stockholders' Meeting of Aries Ventures will take place at 9:00 a.m. PST, on January 17, 2006 at the Doubletree Hotel, 11915 El Camino Real, San Diego, California. Stockholders of Aries Ventures of record on December 2, 2005 will be eligible to vote at the meeting.
(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO )
Stockholders will be asked to elect directors and to approve several other proposals, including the adoption of an Agreement and Plan of Merger providing for the merger of Aries Ventures Inc., a Nevada corporation, into Cardium Therapeutics, Inc., a Delaware corporation. Assuming the merger is approved, Cardium would be the surviving corporation, effectively changing the Company's state of incorporation from Nevada to Delaware and changing the Company's name to Cardium Therapeutics, Inc. More information about the proposals and the Stockholders' Meeting can be found in our definitive proxy statement filed with the SEC and available for review on our website at http://www.cardiumthx.com under "Investors -- SEC Filings."
"This is a very exciting time to be a stockholder in our Company. Having our new Board in place and our corporate reorganization completed will allow us to move forward with business strategies directed to enhancing stockholder value," stated Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium Therapeutics and Aries Ventures.
About the Company
Cardium Therapeutics, Inc. and its parent Aries Ventures Inc. (the Company), headquartered in San Diego, are primarily focused on interventional cardiology and the development and commercialization of non-surgical cardiovascular gene therapeutics. The Company's lead product candidate, Generx(TM), is a non-surgical angiogenic therapy designed to be a one-time treatment for patients with recurrent angina due to coronary artery disease. Generx and the related cardiovascular technology platform were pioneered by Collateral Therapeutics, a San Diego-based biotechnology company co-founded by the Company's CEO Christopher Reinhard. In 1996, Schering AG Germany and Collateral Therapeutics entered into a strategic partnership to develop angiogenic DNA-based therapeutics, including Generx. Based on the advancing clinical progress of Generx, Schering AG acquired Collateral Therapeutics in 2002. In October 2005, the Company announced the acquisition of a portfolio of cardiovascular growth factor therapeutics from Schering AG Germany, including the later-stage product candidate, Generx, and simultaneously merged with a specially formed subsidiary of Aries Ventures Inc. and completed a $30 million financing. For more information about the Company and its product candidates, please visit http://www.cardiumthx.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that our proposed reorganization or business strategies will enhance stockholder value, that required clinical trials will be successful, that necessary regulatory approvals will be obtained, or that the proposed treatments will prove to be safe or effective. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, our limited experience in the development of DNA-based cardiovascular therapeutics, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings made by us with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.
Copyright 2006 Cardium Therapeutics, Inc. All rights reserved. Terms of Use Privacy Policy. Cardium Therapeutics(TM) and Generx(TM) are trademarks of Cardium Therapeutics, Inc.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comCardium Therapeutics, Inc.CONTACT: Press, Investor Contact - Bonnie Ortega, Director, Investor,Public Relations of Cardium Therapeutics, Inc., +1-858-436-1018,InvestorRelations@cardiumthx.com
Web site: http://www.cardiumthx.com/
